Introduction
Cluster of differentiation 36 (CD36) is abundantly expressed in cardiac muscle 1 and partially regulates the rate of myocardial fatty acid uptake in humans. 2 It has been reported that CD36 deficiency is associated with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), [3] [4] [5] but the influence of CD36 deficiency in the heart has not been investigated in detail and pathological reports are scarce. We incidentally diagnosed CD36 deficiency in a heart failure patient with mitral valve prolapse (MVP), based on the absence of myocardial 123 l-15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP) uptake by myocardial scintigraphy. Advanced myocardial damage was found histologically in heart muscle obtained surgically. In the present case, CD36 deficiency may have accelerated heart failure with co-existing MVP before it resulted in a distinct phenotype of primary cardiomyopathies.
Timeline Case presentation
A 52-year-old man began to be treated for hypertension in 2006 and blood pressure had been controlled since then and did not have the other any comorbidities. He was aware of dyspnoea in the summer of 2016 and cardiomegaly was noted in a chest X-ray as part of a medical checkup in August 2017. On admission to our hospital, his blood pressure and heart rate were 118/78 mmHg and 66/min, respectively. Heart sounds showed mid-systolic click with systolic murmur. Abnormal lung sound was not noted. Leg oedema was shown and New York Heart Association (NYHA) classification was Class III. Left ventricular systolic dysfunction with severe hypokinesis in inferior area and MVP with severe mitral regurgitation (MR) were noted by echocardiography (Supplementary material online, Figure S1 ). Left ventricular internal diameter in diastole, left ventricular internal diameter in systole, and left ventricular ejection fraction were 67.6 mm, 56.0 mm, 34.9%, respectively. We started the usual medical treatment for heart failure and performed further examinations. Treatment with beta blocker, angiotensin II receptor blocker, calcium channel blocker, and diuretics was started and brain natriuretic peptide improved from 401 pg/mL to 167 pg/mL. Neither the characteristics of systemic disorders such as Marfan syndrome and EhlersDanlos syndrome nor a family history of cardiac diseases including cardiomyopathy, sudden cardiac death, or MVP were noted. In addition, there were no indications of previous infection, hormonal diseases, diabetes, intake of cardiotoxic material, or cardiac hypertrophy due to hypertension. Mild hypokinesis in the inferior wall was detected by echocardiography (Supplementary material online, Figure S1 ) and perfusion defect was detected by thallium scintigraphy, but angiography did not reveal coronary artery disease. Intramural delayed enhancement with a linear pattern was detected in the interventricular septum by contrast-enhanced magnetic resonance imaging. This patient showed heart failure with reduced ejection fraction (HFrEF). However, the morphological and functional phenotype could not be associated with major prototypical cardiomyopathies such as HCM or DCM.
Notably, the heart lacked BMIPP uptake by BMIPP scintigraphy and showed increased . These results suggested that cardiomyocytes exhibited reduced free fatty acid metabolism and enhanced glucose metabolism. We diagnosed type 1 CD36 deficiency, where both platelets and monocytes lack CD36 by flow cytometry (Supplementary material online, Figure  S2 ). The surgical procedures considered were mitral valve replacement, tricuspid annuloplasty, and left atrial appendage closure, but not mitral annuloplasty. In the latest European Society of Cardiology guideline, 6 MVP constitutes a Class I recommendation for patients with MVP and severe MR. But in the secondary or functional MR which results from an imbalance between closing and tethering forces on the valve secondary to alterations in left ventricular geometry, mitral valve replacement should be considered in patients with unfavourable morphological characteristics. Because of the presence of CD36 deficiency, we were worried about a dysfunctional mitral valve base which could lead to a future exacerbation of mitral valve regurgitation. There was no ruptured mitral chordae tendineae or mitral leaflet perforation. The histological observations of mitral valve showed mild myxoid change and hyalinosis without any specific changes (Supplementary material online, Figure S3 ). Cardiac muscle was biopsied from the posterior wall of the left ventriculum during surgical procedures. Conventional histological observation revealed hypertrophic cardiomyocytes with enlarged nuclei and myofibrillar loss. Perivascular and interstitial fibrosis (i.e. reactive fibrosis but not replacement fibrosis) were moderately associated ( Figure 2) . The microvascular structure around the cardiomyocytes was highlighted by immunohistochemical staining for CD31 (platelet endothelial cell adhesion molecule-1 (PECAM-1)) ( Figure 3A ), but CD36 expression was absent in the myocardial tissue ( Figure 3B ). No specific condition was suggested by transmission electron microscopy (data not shown). After 6 months from surgical procedure, the heart failure was improved and NYHA classification was changed from Class III to Class I. In echocardiography, paravalvular MR was not observed and left ventricular ejection fraction was 44.4%. 
Discussion
We encountered a case of Type 1 CD36 deficiency with MVP. Cluster of differentiation 36 deficiency was incidentally found in a heart failure patient. However, loss of myocardial CD36 expression and an advanced cardiomyopathic histology, including compensative hypertrophy, myofibrillar loss, and reactive fibrosis, were confirmed at the post-operative examination. Latent CD36 deficiency-related cardiomyopathy may have accelerated heart failure with co-existing MVP.
Cluster of differentiation 36 is expressed in vascular endothelial cells and cardiomyocytes, where it regulates the rate of myocardial fatty acid uptake in humans. 2 While free fatty acid is a major energy source in the healthy heart, in CD36 deficiency, the heart needs to metabolize other energy sources. It has been reported that, while myocardial concentrations of adenosine triphosphate and phosphocreatine are maintained, genes related to fatty acid metabolism are reduced and those related to ketone body metabolism and glucose metabolism are increased in CD36 knockout mouse. 7 Changes in metabolism may be associated with myocardial damage related to heart failure and cardiomyopathies, but the detailed mechanism remains to be elucidated. 1, 8 It has been reported that CD36 deficiency is associated with HCM. 5, 9 Kusaka et al. 4 reported that treatment with Sulfo-Nsuccinimidyl palmitate, an inhibitor of fatty acid transporter, increased heart weight in rat. It has also been reported that CD36 deficiency is associated with DCM. 3 Hirooka et al. 3 reported that improvement of cardiac function by medical treatment was associated with an increase in fatty acid metabolism in a patient with both DCM and CD36 deficiency. Tanaka et al. 5 reviewed 14 cases of CD36 deficiency including HCM, DCM, and pressure-overload cardiac hypertrophy. In the present case, heart failure was not based on such typical phenotypes of primary cardiomyopathies. However, left ventricular histology showed non-specific but advanced myocardial degeneration. Thus, we found CD36-related cardiomyopathy along with exacerbated heart failure with MVP. Mitral valve prolapse, which is defined as abnormal slack of the mitral valve leaflets into the left atrium, afflicts 2-3% of the general population. 10 Mitral valve prolapse may be hereditary, especially regarding connective tissue disorders such as Marfan syndrome and obstructive HCM. In the present case, no specific hereditary background or mechanical complication of ischaemic heart disease was noted. Although the influence of CD36 deficiency on the development of MVP cannot be fully excluded, the mitral valve morphology was not much different than those in usual MVP cases. The incidence of MVP is much greater than that of CD36 deficiency, and there has been no previous report of a case of CD36 deficiency with MVP. Taken together, our findings suggest that CD36 deficiency and MVP may have occurred together by chance. Not all cases of MVP without progression of MR and heart failure require surgical treatment.
Various causes of the progression of MVP have been suggested: for example, genetic modifiers, environmental factors (smoking, diet, body mass index, and hypertension), and non-modifiable characteristics such as race and sex. 11 In the present case, co-existing CD36 deficiency-related cardiomyopathy and MVP may have promoted the progression of heart failure. Cardiac function improved after surgery, but we continue to carefully watch this case for the progression of cardiomyopathy.
Conclusion
We presented a case of Type 1 CD36 deficiency-related cardiomyopathy with MVP. In Japan and other Asian countries, a relatively larger percent of the population is expected to carry CD36 deficiency than elsewhere. 12 BMIPP scintigraphy might be helpful for predicting CD36 deficiency for patients with unexplained left ventricular dysfunction. It should be noted that latent CD36 deficiency-related cardiomyopathy may accelerate heart failure with co-existing heart diseases. Further studies will be needed to clarify the cardiac involvement of CD36 deficiency. 
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